Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Myeloproliferative neoplasms (incl. CML)
Trial Status:  Active
Results 1-25 of 407 for your search:
Start Over
Polyethylene Glycol (PEG) Versus Sennosides Study in Opioid-Induced Constipation in Cancer Patients
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: H0901329, NCT01189409
Paracetamol for Cancer Pain
Phase: Phase IV
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: Par 06-0045, NCT01313247
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Anti-thymocyte Globulins for Graft-versus-host Disease Prophylaxis
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 40 to 60
Sponsor: Other
Protocol IDs: 2013-08, NCT01856803
Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: Children
Sponsor: Other
Protocol IDs: GH-IGF-1 AXIS AND CML, NCT01901666
A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IMA_CML_IV, NCT02204722
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1871039, 2013-003250-25, NCT02228382
Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: IMAGE-201, NCT02317159
Multicenter, Phase?, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib
Phase: Phase IV
Type: Supportive care, Treatment
Status: Approved-not yet active
Age: 19 and over
Sponsor: Other
Protocol IDs: 2014-01-112, NCT02389920
CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients
Phase: Phase III, Phase II
Type: Supportive care
Status: Active
Age: 18 months to 21 years
Sponsor: Other
Protocol IDs: #1R01FD003410-01, R01 FD003410-01-A1, NCT00999713
Low-energy Laser Therapy for Prevention of Oral Mucositis in Children
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 0 to 18
Sponsor: Other
Protocol IDs: CHU-0060, NCT01007617
Unrelated Double Umbilical Cord Blood Units Transplantation
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 1 to 50
Sponsor: Other
Protocol IDs: HORCSCT-0902, NCT01015742
The Effect of Xolair ® (Omalizumab) in Mastocytosis Patients
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CIGE025ACH03T V1, NCT01333293
Cladribine Plus Pegylated Interpheron Alfa-2a in Systemic Mastocytosis
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EC11-187, NCT01602939
Evaluation of Plasmatic Levels of Busulfan in Patients Undergoing Hematopoietic Stem Cell Transplantation
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: Busulfan-2013, NCT01800643
MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis
Phase: Phase III, Phase II
Type: Supportive care
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MSC-CY-Russia, NCT02270307
Palifermin for the Reduction of Oral Mucositis in Single-dose Evaluation (PROMISE)
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20040212, UCLA-0412042-01, AMGEN-20040212, NCT00109031
Stem Cell Transplant for Hematological Malignancy
Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
Comparing Ciprofloxacin (CPFX) With Cefepime (CFPM) in Febrile Neutropenic Patients With Hematologic Diseases
Phase: Phase III
Type: Supportive care
Status: Active
Age: 15 to 79
Sponsor: Other
Protocol IDs: C-SHOT 0402, NCT00137787
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CSTI571AAT06, NCT00327262
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: SHEBA-06-4015-IH-CTIL, NCT00297570
Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies
Phase: Phase III
Type: Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: SCT 0307, NCT00619879
Trial of a Breathlessness Intervention Service for Intractable Breathlessness
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PB-PG-0107-11134, ISRCTN04119516, NCT00678405
A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Smouldering Systemic, Indolent Systemic or Cutaneous Mastocytosis With Handicap
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB06006, NCT00814073
Exercise During Chemotherapy for Patients With Hematological Malignancies
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: EA4/031/09, NCT00884364
Start Over